Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Repros' Proellex successful in mid-stage uterine fibroid studies; shares ahead 16% after hours

Published 11/14/2016, 05:04 PM
Repros' Proellex successful in mid-stage uterine fibroid studies; shares ahead 16% after hours
  • Thinly traded nano cap Repros Therapeutics (NASDAQ:RPRX) is up 16% after hours on increased volume in response to its announcement of positive results from two Phase 2 studies assessing oral and vaginal delivery of Proellex (telapristone acetate) for the treatment of uterine fibroids.
  • Both studies enrolled women with confirmed fibroids at baseline and experiencing more than 80 mL of blood loss during menses. Participants were administered both 6 mg and 12 mg doses, by either route for 18 weeks followed by a treatment-free phase to allow for menses. After menses occurred, a second 18-week course of treatment was conducted.
  • At the end of the second course of treatment, 92.9% of subjects treated with oral Proellex achieved amenorrhea (absence of menstruation) while only 50% of the vaginally treated group did. In the orally administered group, 100% of subjects receiving the 12 mg dose achieved amenorrhea while 88.9% of the 6 mg group stopped menses.
  • The company intends to advance orally administered Proellex to Phase 3 development.
  • Proellex is a small molecule compound that selectively blocks the progesterone receptor.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.